Why are Ansell shares on investors' radars today?

Management sees the deal growing sales and earnings.

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ansell Ltd (ASX: ANN) shares are in focus today after the company announced it finalised a major acquisition.

The purchase was made for all of the assets in US-listed entity Kimberly-Clark Corporation (NYSE: KMB)'s personal protective equipment (PPE) business – a deal Ansell initially announced on 8 April 2024.

Despite the completion of this major acquisition, Ansell shares remain steady at $25.90 per share at the time of writing, flat with the previous close of $25.91 apiece. Here's a closer look.

Ansell shares on radar after transaction

Kimberly-Clark is a US consumer goods giant, holding over 175 brands under its banner. Many are household names – Kleenex tissues and Huggies diapers are two examples.

It has a market capitalisation of US$47.8 billion at the time of writing.

The rationale behind the deal was to expand Ansell's product portfolio and market position. The $970 million transaction will see it acquire brands like Kimtech and KleenGuard – both used for anti-contamination against bacteria and viruses.

It also includes several manufacturing assets used in the production of gloves, masks, apparel, and eyewear.

Financial implications

The deal was finalised today after Ansell secured long-term debt financing to settle the balance.

It raised US$377 million via the United States Private Placement (USPP) market. The other portion of the deal was funded through a fully underwritten institutional placement of approximately 17.8 million new Ansell shares on 8 April, where it raised $400 million at $22.45 per share.

Since that date, these investors have made a 15% return on their money as I write.

The new debt facility announced today will replace previous instruments Ansell was using to fund its growth. As such, management noted this should provide Ansell with financial stability going into FY 2025:

The USPP proceeds replace the previously announced fully committed bridge facility which will no longer need to be drawn, with maturities on the notes issued ranging from 5 to 12 years and providing Ansell with long term funding certainty going into FY25.

Outlook for Ansell shares

Despite the size and potential impact of the acquisition, Ansell shares have not seen immediate movement in early trade on Tuesday.

Investors might be taking a wait-and-see approach, considering the complexities and integration efforts associated with such a significant purchase.

But analysts appear to be optimistic about the deal's long-term benefits. According to CommSec, Anshell shares are rated as a moderate buy, with 6 buy and 6 hold recommendations, respectively.

Ansell's management also expects the acquisition to be beneficial. It expects revenues and earnings per share (EPS) to grow directly as a result of the move. We will just have to wait and see if this is positive for Ansell shares or not.

The company's full-year results for FY 2024 are set to be released on 20 August, per the announcement.

In the last 12 months, Ansell shares have slipped over 4.5% into the red. This year to date, the stock has lifted into the green following a 6% return in the past month of trade.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 113% in a year, guess which ASX 200 healthcare stock just scored another FDA win

The ASX 200 healthcare stock received another FDA approval for its cancer detection product.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Telix shares slip 11% from highs. Time to buy this high flying biotech?

Is now the time to look at the biotech flyer?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Up 200% in a year! Why is this ASX healthcare stock rocketing today?

This stock just can't stop rising. What is it this time?

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Earnings Results

Sigma shares climb after reporting massive 878% profit jump for FY25

Big profits have been reported from this pharmacy chain giant this morning.

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 13%! Check out the latest ASX stock to receive FDA approval

Big news is giving this stock a lift on Thursday. Here's what is happening.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Healthcare Shares

Guess which ASX stock is surging 11% on big US FDA news

Big news is lifting this stock higher on Wednesday. Let's find out what's happening.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Bell Potter says this ASX 200 share can rise 120%

Let's see what the broker is saying about this beaten down stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why is this ASX 200 healthcare share leaping 14% today?

Clarity Pharmaceuticals is the biggest gainer of the ASX 200 on Tuesday.

Read more »